Alkermes Invests In Novel CNS Targets With Rodin Acquisition
Executive Summary
Rodin is developing HDAC CoREST complex inhibitors for neurological conditions, with a lead candidate having completed Phase I testing. Alkermes will pay $100m upfront.
You may also be interested in...
Finance Watch: New Funding Available For Antibacterials, Start-Ups
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
Alkermes’ Pops Lays Out Novel Drug Vision For Year Ahead
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Need a specific report? 1000+ reports available
Buy Reports